



August 21, 2020

FunPep Co., Ltd.

Announcement of Fund Raising through Third Party Allocation of New Shares

FunPep Co., Ltd. ("FunPep") is pleased to announce that it has raised a total of approximately 1.5 billion yen through a third-party allocation of new shares to funds managed by SBI Investment, Shinsei Capital Partners, Yamaguchi Capital, Bio-Sight Capital, and EPS Holdings.

FunPep is a university-launched drug discovery biotech company established to commercialize the results of research on functional peptides conducted at the Osaka University Graduate School of Medicine.

The functional peptide SR-0379, which was created based on the results of research at Osaka University, is now in the preparatory stage of Phase III clinical trials in Japan as a treatment for skin ulcers such as pressure ulcers under a partnership with Shionogi & Co. In addition, FunPep has established a drug discovery platform technology "STEP UP" built on the strength of functional peptide AJP001 (a peptide that shows adjuvant-like action), and we are promoting the research and development of "antibody-inducing peptides", therapeutic vaccines for chronic diseases such as inflammatory and allergic diseases.

With this fundraising round, we will further develop and expand these R&D pipelines and strive to increase our corporate value.